Mitochondrial donation - hope for families with mitochondrial DNA disease.
Level 5 - mechanism / opinion, no new human data
Narrative review and policy overview containing no primary clinical data.
PubMed 32573698 · doi:10.1042/ETLS20190196
What was done
This narrative review describes the UK's 2015 legislative approval of mitochondrial donation, the creation of a dedicated National Health Service (NHS) clinical service offering reproductive options to carriers of pathogenic mitochondrial DNA (mtDNA) mutations, and an associated research protocol monitoring outcomes in resulting children at 18 months of age.
What was found
The abstract reports no empirical findings, statistical data, or clinical metrics. It describes the regulatory and clinical translation process that enabled the implementation of an active NHS service and follow-up study.
Why it matters
It outlines the framework used in the UK to transition mitochondrial replacement techniques from experimental laboratory procedures into an approved clinical pathway for preventing inherited mitochondrial disease.
Limits
The abstract provides only a qualitative overview with no primary patient data, cohort sizes, success rates, safety outcomes, or developmental findings from the treated cases.
Cited by
- supports Mitochondrial replacement therapy (three-parent IVF) has been approved in England to prevent the transmission of mitochondrial diseases.